Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alexion Pharmaceuticals Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 1992
Status: Acquired
BioCentury | Oct 29, 2024
Deals
Novartis adds another degrader, this time from Monte Rosa
Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Jun 25, 2024
Product Development
Alnylam: ‘Big win’ amyloidosis readout sets up Amvuttra as standard of care
After endpoint was changed, hotly anticipated HELIOS-B readout meets primary, secondaries as monotherapy, combination
BioCentury | Jun 21, 2024
Management Tracks
ITM names Cavey CEO, plus PureTech, Brainstorm and more
Plus: New chairs for PureTech, Evexta and updates from PharmaEssentia, Brainstorm, Danaher and more
BioCentury | Jan 26, 2024
Finance
Parlaying its biotech brand, J.P. Morgan building venture business
New investment strategy, anchored by bank and led by Stephen Squinto, targets 20-25 deals, including company creation
BioCentury | Nov 29, 2023
Management Tracks
Camille Bedrosian named Amylyx CMO
Plus: Cameron Turtle becomes CEO of Spyre, and updates from Ocuphire and Astraveus
BioCentury | Nov 9, 2023
Regulation
Nov. 8 Quick Takes: FDA approves Lilly’s tirzepatide for weight loss
Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more
BioCentury | Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Sep 1, 2023
Management Tracks
Huguet to succeed Mayer at Ipsen
Plus: Junshi COO Hui departing, Kaufmann named CSO at Hansa
Items per page:
1 - 10 of 904